Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: Could it be the first step of the treatment?

Autoimmunity Reviews

Volumn 13, Issue 1, 2014, Pages 49-53

  Caporali, Roberto ^a   Bugatti, Serena ^a   Cavagna, Lorenzo ^a   Antivalle, Marco ^b   Sarzi Puttini, Piercarlo ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Abatacept; Rheumatoid arthritis; T cells

Indexed keywords

ABATACEPT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; METHOTREXATE; PLACEBO;

DISEASE ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEADACHE; HUMAN; INFECTION; NAUSEA; NONHUMAN; PROGNOSIS; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE;

ABATACEPT; RHEUMATOID ARTHRITIS; T CELLS;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; HUMANS; LYMPHOCYTE ACTIVATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84886952210     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.06.008     Document Type: Review

References (44)

1. Nell V.P., Machold K.P., Eberl G., Stamm T.A., Uffmann M., Smolen J.S. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004, 43:906-914.
2. Schoels M., Knevel R., Aletaha D., Bijlsma J.W., Breedveld F.C., Boumpas D.T., et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010, 69:638-643.
3. Gaujoux-Viala C., Smolen J.S., Landewé R., Dougados M., Kvien T.K., Mola E.M., et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010, 69:1004-1009.
4. Smolen J.S., Aletaha D., Koeller M., Weisman M.H., Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007, 370:1861-1874.
5. Caporali R., Pallavicini F.B., Filippini M., Gorla R., Marchesoni A., Favalli E.G., et al. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 2009, 8:274-280.
6. Caporali R., Caprioli M., Bobbio-Pallavicini F., Bugatti S., Montecucco C. Long term treatment of rheumatoid arthritis with rituximab. Autoimmun Rev 2009, 8:591-594.
7. Fiocco U., Sfriso P., Oliviero F., Pagnin E., Scagliori E., Campana C., et al. Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept. Autoimmun Rev 2008, 8:76-82.
8. Panayi G.S., Lanchbury J.S., Kingsley G.H. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992, 35:729-735.
9. Goronzy J.J., Weyand C.M. Interplay of T lymphocytes and HLA-DR molecules in rheumatoid arthritis. Curr Opin Rheumatol 1993, 5:169-177.
10. Alzabin S., Williams R.O. Effector T cells in rheumatoid arthritis: lessons from animal models. FEBS Lett 2011, 585:3649-3659.
11. Klimiuk P.A., Yang H., Goronzy J.J., Weyand C.M. Production of cytokines and metalloproteinases in rheumatoid synovitis is T cell dependent. Clin Immunol 1999, 90:65-78.
12. Weinstein J.S., Hernandez S.G., Craft J. T cells that promote B-Cell maturation in systemic autoimmunity. Immunol Rev 2012, 247:160-171.
13. Kotake S., Udagawa N., Hakoda M., Mogi M., Yano K., Tsuda E., et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001, 44:1003-1012.
14. Issacs J.D., Greer S., Sharma S., Symmons D., Smith M., Johnston J., et al. Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. Arthritis Rheum 2001, 44:1998-2008.
15. Harding F.A., McArthur J.G., Gross J.A. CD28 mediated signaling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992, 356:607-609.
16. Karandikar N.J., Vanderlugt C.L., Walunas T.L., Miller S.D., Bluestone J.A. CTLA-4: a negative regulator of autoimmune disease. J Exp Med 1996, 184:783-788.
17. Genovese M.C., Covarrubias A., Leon G., Mysler E., Keiserman M., Valente R., et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 2011, 63:2854-2864.
18. Kremer J.M., Dougados M., Emery P., Durez P., Sibilia J., Shergy W., et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52:2263-2271.
19. Kremer J.M., Genant H.K., Moreland L.W., Russell A.S., Emery P., Abud-Mendoza C., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006, 144:865-876.
20. Schiff M., Keiserman M., Codding C., Songcharoen S., Berman A., Nayiager S., et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008, 67:1096-1103.
21. Westhovens R., Kremer J.M., Moreland L.W., Emery P., Russell A.S., Li T., et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol 2009, 36:736-742.
22. Kremer J.M., Genant H.K., Moreland L.W., Russell A.S., Emery P., Abud-Mendoza C., et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008, 58:953-963.
23. Genant H.K., Peterfy C.G., Westhovens R., Becker J.C., Aranda R., Vratsanos G., et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2008, 67:1084-1089.
24. Kremer J.M., Russell A.S., Emery P., Abud-Mendoza C., Szechinski J., Westhovens R., et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis 2011, 70:1826-1830.
25. Schiff M., Keiserman M., Codding C., Songcharoen S., Berman A., Nayiager S., et al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. Ann Rheum Dis 2011, 70:2003-2007.
26. Peterfy C.G., Countryman P., Gabriele A., Shaw T., Anisfeld A., Tsuji W., et al. Magnetic resonance imaging in rheumatoid arthritis clinical trials: emerging patterns based on recent experience. J Rheumatol 2011, 38:2023-2030.
27. Conaghan P.G., Durez P., Alten R.E., Burmester G.R., Tak P.P., Klareskog L., et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann Rheum Dis 2012, 10.1136/annrheumdis-2012-201611.
28. Bugatti S., Caporali R., Manzo A., Sakellariou G., Rossi S., Montecucco C. Ultrasonographic and MRI characterisation of the palindromic phase of rheumatoid arthritis. Ann Rheum Dis 2012, 71:625-626.
29. McQueen F.M. Bone marrow edema and osteitis in rheumatoid arthritis: the imaging perspective. Arthritis Res Ther 2012, 14:224.
30. Weisman M.H., Durez P., Hallegua D., Aranda R., Becker J.C., Nuamah I., et al. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol 2006, 33:2162-2166.
31. Buch M.H., Boyle D.L., Rosengren S., Saleem B., Reece R.J., Rhodes L.A., et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009, 68:1220-1227.
32. Bugatti S., Manzo A., Bombardieri M., Vitolo B., Humby F., Kelly S., et al. Synovial tissue heterogeneity and peripheral blood biomarkers. Curr Rheumatol Rep 2011, 13:440-448.
33. Breedveld F.C., Weisman M.H., Kavanaugh A.F., Cohen S.B., Pavelka K., van Vollenhoven R., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54:26-37.
34. Emery P., Breedveld F.C., Hall S., Durez P., Chang D.J., Robertson D., et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008, 372:375-382.
35. Yazici Y., Moniz Reed D., Klem C., Rosenblatt L., Wu G., Kremer J.M. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data. Clin Exp Rheumatol 2011, 29:494-499.
36. Westhovens R., Robles M., Ximenes A.C., Nayiager S., Wollenhaupt J., Durez P., et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009, 68:1870-1877.
37. Bathon J., Robles M., Ximenes A.C., Nayiager S., Wollenhaupt J., Durez P., et al. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis 2011, 70:1949-1956.
38. Olivieri I., Sarzi-Puttini P., Bugatti S., Atzeni F. d'Angelo S, Caporali R. Early treatment in early undifferentiated arthritis. Autoimmun Rev 2012, 11:589-592.
39. Smolen J.S., Landewé R., Breedveld F.C., Dougados M., Emery P., Gaujoux-Viala C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
40. Caporali R., Conti F., Alivernini S., Atzeni F., Seriolo B., Cutolo M., et al. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. Clin Exp Rheumatol 2011, 29(3 Suppl. 66):S7-S14.
41. Bugatti S., Manzo A., Caporali R., Montecucco C. Assessment of synovitis to predict bone erosions in rheumatoid arthritis. Ther Adv Musculoskelet Disord 2012, 4:235-244.
42. Singh J.A., Furst D.E., Bharat A., Curtis J.R., Kavanaugh A.F., Kremer J.M., et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012, 64:625-639.
43. Dimitroulas T., Nikas S.N., Trontzas P., Kitas G.D. Biologic therapies and systemic bone loss in rheumatoid arthritis. Autoimmun Rev Mar 29 2013, pii: S1568-9972(13)00047-5. [Epub ahead of print]. 10.1016/j.autrev.2013.03.015.
44. Atzeni F., Benucci M., Sallì S., Bongiovanni S., Boccassini L., Sarzi-Puttini P. Different effects of biological drugs in rheumatoid arthritis. Autoimmun Rev 2013, 12:575-579.